<DOC>
	<DOCNO>NCT02765594</DOCNO>
	<brief_summary>Immunoglobulin A nephropathy ( IgAN ) common primary glomerulonephritis world.There date curative therapy patient IgAN.It consider dendritic cell , Toll-like receptor ( TLR ) 9 cytokine interleukin-6 ( IL-6 ) , interferon-alpha ( IFN-a ) tumor necrosis factor-alpha ( TNF-α ) , play important role aberrant mucosal response . Hydroxychloroquine antimalarial agent notable impact immune activation reduction circulate activate immune cell include decreased TLR-expressing cell , reduce IFN-secreting plasmacytoid dendritic cell , reduce production inflammatory cytokine include interferon alpha , IL-6 TNF alpha . Recent study show hydroxychloroquine benefit renal remission could retard onset renal damage patient lupus nephritis . hydroxychloroquine may potential effect IgA nephropathy , alleviate proteinuria renal protect effect . This single center , prospective , randomize , control study ass utility hydroxychloroquine IgAN patient .</brief_summary>
	<brief_title>Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria IgA Nephropathy</brief_title>
	<detailed_description>Immunoglobulin A nephropathy ( IgAN ) common primary glomerulonephritis world . Its estimated frequency least 2.5 case per year per 100,000 adult . The glomerulopathy usually progress slowly leading end stage renal disease ( ESRD ) . ESRD develop 20 % -40 % patient 20 year . Given complex yet incompletely understood pathogenetic mechanism , date curative therapy patient IgAN . Although pathogenesis IgAN still obscure , underglycosylated IgA-containing immune-complex include IgG IgA antibodies hinge region IgA1 key factor IgA nephropathy . Aberrant mucosal immune response might lead increase production underglycosylated IgA1 . It consider dendritic cell , Toll-like receptor ( TLR ) 9 , cytokine interleukin-6 ( IL-6 ) , , interferon-alpha ( IFN-a ) tumor necrosis factor-alpha ( TNF-α ) , play important role aberrant mucosal response . Hydroxychloroquine antimalarial agent notable impact immune activation reduction circulate activate immune cell include decreased TLR-expressing cell , reduce IFN-secreting plasmacytoid dendritic cell , reduce production inflammatory cytokine include interferon alpha , IL-6 TNF alpha . Recent study show hydroxychloroquine benefit renal remission could retard onset renal damage patient lupus nephritis . Therefore , hydroxychloroquine , target dendritic cell , TLR , IL-6 , IFN-α TNF-α，may potential effect IgA nephropathy , alleviate proteinuria renal protect effect . This single center , prospective , randomize , control study ass utility hydroxychloroquine add valsartan IgAN patient .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Proteinuria</mesh_term>
	<mesh_term>Glomerulonephritis , IGA</mesh_term>
	<mesh_term>Hydroxychloroquine</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<mesh_term>Molecular Mechanisms Pharmacological Action</mesh_term>
	<criteria>1. biopsy proven primary IgA nephropathy 2. age 1860 year 3. proteinuria range 0.5 1.5g/d 4. serum creatinine ≤132.6μmol/L 5. normal blood pressure blood pressure ≤130/80 mmHg patient hypertension 1 . Hypersensitivity chloroquine hydroxychloroquine 2. blood pressure &lt; 90/60 mm Hg 3. pregnancy breastfeed woman 4. renal artery stenosis 5 . Rapidly progressive renal insufficiency 6. systemic lupus erythematosus connective tissue diseases 7 . Henoch schoenlein purpura 8. nephritis 9. diabetes mellitus 10. retinopathy 11. contraindication hydroxychloroquine 12. severe hepatic insufficiency 13 . G6PD deficiency 14. psoriasis porphyria 15. malignant hypertension 16. viral hepatitis infection 17. treatment steroid cytotoxic drug previous three month 18. psychiatric disorder 19. suitable study judge investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Glomerulonephritis , IGA</keyword>
	<keyword>Kidney Diseases</keyword>
	<keyword>Autoimmune Diseases</keyword>
	<keyword>Glomerulonephritis</keyword>
	<keyword>Nephritis</keyword>
	<keyword>Immune System Diseases</keyword>
	<keyword>Urologic Diseases</keyword>
	<keyword>Hydroxychloroquine</keyword>
	<keyword>Anti-Infective Agents</keyword>
	<keyword>Antimalarials</keyword>
	<keyword>Antiparasitic Agents</keyword>
	<keyword>Antiprotozoal Agents</keyword>
	<keyword>Antirheumatic Agents</keyword>
	<keyword>Enzyme Inhibitors</keyword>
	<keyword>Molecular Mechanisms Pharmacological Action</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>interleukin-6</keyword>
	<keyword>interferon-alpha</keyword>
	<keyword>tumor necrosis factor-alpha</keyword>
</DOC>